Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4YA34 | — |
Drug Exposure During Pregnancy; Vaccine administered at 19 weeks of pregnancy; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of inappropriate schedule of vaccine administered in a 33-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 4YA34, expiry date 05-NOV-2027) for prophylaxis. Previously administered products included Boostrix (1st dose received on 07-SEP-2022, batch number-YR7AA and expiry date-14-APR-2024). On 15-SEP-2025, the patient received the 2nd dose of Boostrix. On 15-SEP-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate schedule of vaccine administered (Verbatim: Vaccine administered at 19 weeks of pregnancy). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Drug Exposure During Pregnancy). The outcome of the inappropriate schedule of vaccine administered and vaccine exposure during pregnancy were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in second trimester Estimated Delivery/Due date: 12-FEB-2026 Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-SEP-2025 The patient received Boostrix at 19 weeks of pregnancy. The reporter consented to follow up.